Fig.5

A 41-year-old patient presented with IDC grade 2 ER and PR positive and Her 2 positive planned to receive neoadjuvant chemotherapy and Herceptin. a–d SWE baseline, post-first, second and fourth cycles, respectively. The stiffness ratio in the lesion, their change, and percent change were 6.2, − 5.7, and 47% post-first cycle. Post-second cycle, the stiffness ratio, change in stiffness ratio, and percent change were 6.9, − 5.1, and − 42%, and post-fourth cycle, the stiffness ratio, change in stiffness ratio, and percent change ratio were 5.1, − 6.8, and − 57%. Postoperative pathology revealed npCR (RCBIII)